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Purpose: To present early and midterm results after endovascular stent graft repair of patients with penetrating aortic
ulcers (PAU).
Methods: Between January 1997 and March 2008, a total of 202 patients received thoracic aortic endografting in our
institution, 48 patients (32 men, median age 70 years, range, 48-89) with PAU. A retrospective analysis of these patients
was performed. Thirty-one patients (65%) showed an acute aortic syndrome (8 contained rupture, 23 symptomatic).
Follow-up scheme included postoperative computed tomography angiography prior to discharge, at 3, 6, and 12 months,
and yearly thereafter. Mean follow-up was 31.3 months (1.3-112.6).
Results:Technical success was achieved in 93.7%. Primary clinical success rate was 81.2%. In-hospital mortality was 14.6%.
Perioperative mortality was significantly (P  .036) higher in patients with acute aortic syndrome compared to
asymptomatic patients (22.5% vs 0%). Postoperative complications occurred in 15 patients (31%), including 2 patients
with minor strokes and 6, respectively, 5 patients with cardiac and/or respiratory complications. Early endoleaks were
observed in 9 patients (19%), late endoleaks in another 2 patients. Reintervention was necessary in 4 out of 48 patients
(8.4%). The actuarial survival estimates at 1, 3, and 5 years were 78% 6%, 74% 7%, and 61% 10%, respectively. There
was no aortic-related death during follow-up. Cox regression showed age (hazard ratio [HR]; 1.08, P  .036) and a
maximum aortic diameter >50 mm (HR, 4.92; P  .021) as independent predictors of death.
Conclusion: Endovascular treatment of penetrating aortic ulcers is associated with a relevant morbidity and mortality rate
in frequently highly comorbid patients. Midterm results could prove a sustained treatment success regarding actuarial
survival and aortic-related death. Emergencies show a significantly worse outcome, but treatment is still warranted in
these symptomatic patients. ( J Vasc Surg 2008;48:1361-8.)Successful open surgical repair of a ruptured penetrat-
ing aortic ulcer (PAU) of the descending aorta has first
been reported by Shumacker and King in 1959.1 Since the
1980s, due to substantial improvements in vascular imag-
ing techniques, increasing information regarding the radio-
logical findings and the natural history of this pathology is
available.2,3 Recently, PAUs have been defined as a distinc-
tive entity of the acute aortic syndrome. Therefore, PAUs
gain more and more attention and awareness not only in
the surgical community.4,5
As symptomatic penetrating aortic ulcers show a poor
natural history with rupture rates up to 40%, urgent surgical
repair is commonly warranted.6-8 Currently, poor data
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atic PAUs is available. The present literature indicates a
disease progression with pseudoaneurysm development in
approximately 30-50% of these cases but indication for
surgical treatment still remains unclear.9-11 Over the last
decade, due to its lowmorbidity andmortality compared to
open surgery, thoracic endovascular aortic repair (TEVAR)
has evolved as a first-line treatment modality for thoracic
aortic pathologies in many vascular centers.11 PAUs repre-
sent mainly short and localized lesions, frequently in el-
derly, often high-risk patients which makes them especially
suitable and attractive for endovascular repair.7,12,13 The
aim of this study was, therefore, to evaluate early and
midterm results of TEVAR and to identify risk factors for
early and late death. Additionally, a subgroup analysis of
symptomatic vs asymptomatic patients was performed.
METHODS
Patient population. Between January 1997 and Ma-
rch 2008, a total of 202 patients received thoracic aortic
endografting (TEVAR) in our institution. This includes 34
patients with penetrating aortic ulcers of the thoracic aorta
and 2 patients with concomitant thoracic and infrarenal
PAU. In addition, 12 patients received endovascular aortic
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period. The total study population consists thus of 48
patients (32 men, median age 70 years, range, 48-89).
Baseline characteristics and cardiovascular risk factors
of our patients are given in Table I. For preoperative risk
stratification additive, respectively, logistic EuroScore in
high-risk patients and the American Society of Anesthesi-
ologists (ASA) classification was used.14,15 EuroScore is a
frequently used preoperative risk stratification system for
cardiac and open thoracic aortic surgery. Variables include
demographic, cardiac related, and surgery-related vari-
ables.14,15
The median logEuroScore was 20.3 (2.7-94). ASA
classification was III in 79.2% and IV in 14.5% of the
patients, which demonstrates a highly comorbid patient
cohort. Indications for treatment were aortic rupture in 8
patients (17%), persistent or recurrent pain in 23 patients
(48%), and progression of PAU size or morphological
aspects (eg, diameter, pleural effusion) in the 17 asymp-
tomatic patients (35%). Median interval between onset of
symptoms and the endovascular procedure was 9 days
(range, 0-224).
Additional aortic pathologies were present in 16 out of
48 (33%) patients (acute aortic dissection type Stanford B
n 3, intramural hematoma [IMH] n 7, aortobronchial
fistula [ABF] n 2, thoracic aortic aneurysm [TAA] n 1,
thoracoabdominal aortic aneurysm [TAAA] n  1, and
infrarenal abdominal aortic aneurysm [AAA] n  2).
Both patients with concomitant AAA received simulta-
neous open aneurysm repair, using a 10 mm Dacron graft
as an iliac conduit for TEVAR. The patient with a TAAA
(Crawford type I) and an infrarenal PAU received open
surgical repair of the TAAA and staged infrarenal EVAR to
Table I. Patient characteristics (n  48)
Age (yrs) 70 (48-89)
Gender (male:female) 32:16
ASA classification 3  0,4
Additive EuroScore 10 (3-23)
Logistic EuroScore 20.3 (2.7-94)
Hypertension 48 (100)
Smoking history 34 (71)
Diabetes mellitus 13 (27)
COPD 10 (21)
Renal insufficiency 9 (19)
Coronary artery disease 21 (44)
Previous myocardial infarction 17 (35)
Previous cardiac surgery/coronary intervention 13 (27)
NYHA
I 7 (14)
II 17 (36)
III 5 (11)
IV 1 (2)
Initial presentation with acute aortic syndrome 31 (65)
Previous infrarenal aortic surgery 3 (6)
COPD, Chronic obstructive pulmonary disease; ASA, American Society of
Anesthesiology; NYHA, New York Heart Association; SD, standard devia-
tion.
Values are presented as mean  SD, median (range) or n (%).minimize the risk of paraplegia. For the same reason, thepatient with a TAA and an infrarenal PAU received staged
TEVAR/EVAR of both pathologies. Hybrid procedures
were performed in 6 out of 48 patients (visceral hybrid
procedure n 2, aortic arch hybrid procedure n 4). Our
experience with hybrid procedures has been published re-
cently.16,17
Stent grafts. A total of 58 endografts were implanted.
Forty-one patients received a single stent graft (median, 1;
range, 1-4). Median length and diameter were 150 mm
(95-200) and 34 mm (22-40), respectively. Mean covered
aortic length was 154  51 mm.
For TEVAR, 4 types of stent grafts were implanted: 23
Talent/Valiant (Medtronic Vascular, Santa Rosa, Calif), 28
TAG (W.L. Gore & Associates, Flagstaff, Ariz), and 3
Zenith (Cook Inc, Bloomington, Ind). In the infrarenal
segment, additional 3-stent graft systems were used: 2
Excluder (Gore), 1 AneuRx (Medtronic), and 1 Lifepath
device (Edwards Lifesciences, Irvine, Calif).
Pre-interventional imaging. Endograft sizing was
based on centerline diameter measurements from preoper-
ative contrast enhanced CT- or MR-angiography and three
dimensional (3D) image reconstructions. For stent graft
diameter selection, 15-20% oversizing was applied.
Procedure. All surgical procedures were performed in
an operation theater equipped with fluoroscopic and angio-
graphic capabilities (Series 9800; OEC Medical Systems,
Inc, Salt Lake City, Utah) and a carbon fiber operating
table. For exact visualization of the landing zones in tho-
racic endograft procedures, the patient’s left shoulder was
elevated to 40° with both arms fixed beside the body. Each
patient received single-shot antibiotic therapy and 3000
units of heparin for anticoagulation.
Forty procedures (83%) were performed under general
anesthesia, 4 under spinal/epidural and 4 under local an-
esthesia. Vascular access was obtained by transfemoral inci-
sion in 38 patients; in patients with small femoral arteries
(n  8), a 10-mm Dacron graft conduit was created tem-
porarily to the left common iliac artery. In 2 patients with
AAA, an infrarenal bifurcated graft was used as a conduit.
The procedure protocol has been published before.18 For
exact stent graft positioning in the aortic arch, adenosine-
induced cardiac arrest (AICA) was used in 14 (29%) pa-
tients. According to our protocol, AICA is indicated for any
pathology located proximal to the left subclavian artery.
Nevertheless, it could not be applied in all these cases due
tomissing application knowledge in some emergency cases.
Completion angiography was performed to assess ac-
curate placement and exclusion of the PAU.
Follow-up. Follow-up schedule included postopera-
tive computed tomographic angiography (CTA) before
discharge, clinical examination, plain chest radiography,
and CTA/magnetic resonance angiography (MRA) 6 and
12 months postoperatively and annually thereafter (Fig 1).
No patient was lost to follow-up. Mean follow-up was 31.3
months (1.3-112.6).
Definitions and statistical analysis. Technical and
clinical success were defined according to the reporting
standards for endovascular aortic aneurysm repair.19 En-
ortic
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et al.20 Early endoleaks were defined as apparent on intra-
operative control angiography or primary postoperative
CTA control. Endoleaks occurring during follow-up were
defined as late endoleaks. To classify proximal landing
zones, the aortic arch map with Zone 0-4 by Mitchell et al
was applied.21 Pathology location and distal landing zones
were categorized using a modified (landing zone IVa-c 
V) version of our previously described classification (Fig 2).
A retrospective analysis of the prospectively collected
data was performed. Data are expressed as mean standard
deviation (SD) or median (range). Actuarial survival esti-
mate was generated using the Kaplan-Meier analysis. Log
rank test was used for survival comparison. For subgroup
analysis, Fisher’s exact test and Mann-Whitney U test were
used for categorical respectively continuous variables. All
statistical analysis was performed using XLSTAT (Version
7.5; Addinsoft SARL, New York, NY). Cox proportional
hazard model (Cox regression analysis) was used to identify
Fig 1. Pre- (A)/postoperative (C and D) computed
angiography showing a successfully treated penetrating aindependent preoperative risk factors affecting survival(MedCalc Version 9.5.2, MedCalc software, Mariakerke,
Belgium). A P value  .05 was defined statistically signifi-
cant.
RESULTS
A total of 56 PAU were found in this patient cohort
with 8 patients (17%) having more than one ulcer. Distri-
bution pattern of the pathologies show approximately 50%
of the lesions in the aortic arch and proximal descending
thoracic aorta (Fig 2). Lesion characteristics show a broad
spectrum regarding ulcer depth (mean 23mm 12; range,
5-72) and diameter (mean 22 mm  9; range, 9-50) and
maximum aortic diameter (50 mm  17; range, 27-105)
respectively. In 22 of 36 patients (61%) treated with
TEVAR, the proximal landing zone was within the aortic
arch (Zone 0-3).21 For distal landing zone extension, cov-
ering of the celiac trunk (Zone IVa) without prior revascu-
larization was performed in 2/36 patients (Table II).
Early outcomes. Technical success could be achieved
ography angiography (CTA) and intraoperative (B)
ulcer with stent graft repair.tomin 45/48 patients (93.7%). Two patients showed an en-
JOURNAL OF VASCULAR SURGERY
December 20081364 Geisbüsch et aldoleak type I at the proximal landing zone (Zone 2) on the
first postoperative CTA control, but refused further rein-
terventions. One of these patients (76 years, ASA 4,
logEuroScore 53.5) died 4 months postoperatively of se-
vere pneumonia and the other is under CTA surveillance 6
months postoperatively. One patient (85 years, ASA 4,
logEuroScore 94) died 2 days postoperatively after TEVAR
of a ruptured PAU as a result of a secondary aortic rupture
in the aortic arch proximal to the stent graft. Intraoperative
completion angiography had shown no endoleak and the
Table II. Proximal and distal landing zone characteristics
Proximal landing zone diameter (mm) 27  4
Proximal landing zone
Zone 0 2 (4)
Zone 1 4 (8)
Zone 2 6 (12)
Zone 3 10 (20)
Zone 4 14 (28)
Infrarenal 14 (28)
Distal landing zone diameter (mm) 25  5
Distal landing zone
Zone I 0
Zone II 0
Zone IIIa 20 (40)
Zone IIIb 12 (24)
Zone IVa 2 (4)
Zone IVb 0
Zone IVc 0
Infrarenal aorta 12 (24)
Iliac artery 4 (8)
SD, Standard deviation.
Values are presented as mean  SD (range), median (range) or n (%).
Table III. Postoperative morbidity and mortality
ICU stay (d) 1 (0-20)
Primary endoleak 9 (18.7)
Type I 2
Type II 6
Type IV 1
Secondary endoleak 2 (4.2)
Type I 1
Type II 0
Type IV 1
Early conversion 0
Late conversion 1
Postoperative complications 15/48 (31.2)
Neurological complications
Stroke/TIA 2
Paraplegia 0
Cardiac complication 6
Respiratory complications 5
Wound infection 3
Aorto-esophageal fistula 2
Renal failure 2
Bleeding 1
Aortic rupture 1
30-day mortality 3 (6.2)
In-hospital mortality 7 (14.6)
Reintervention 4 (8.3)
Values are presented as median (range) or n (%).autopsy revealed the stent graft in the correct position withsuccessful exclusion of the PAU. The reason for this rup-
ture remained unclear, manipulation with stiff guidewires
or the nose cone of the stent graft might be an unprovable
explanation. No early conversion was necessary.
Early endoleaks were observed in 9 patients (19%)
(Table III). This includes 2 patients with an endoleak type
I described above. Another patient showed a persistent
endoleak type II via the celiac trunk and received successful
embolization. One patient needed late conversion 11
months after EVAR of an infrarenal PAU due to sac en-
largement as a result of a persistent endoleak of unknown
origin. Intraoperatively, material fatigue with an endoleak
type IV could be verified. An additional 5 patients with an
endoleak type II, which all sealed spontaneously, were
noticed.
Thirty-day mortality rate was 6.2% (3/48), in-hospital
mortality was 14.6% (7/48). The causes of death in these 7
patients were aortic rupture (n  1), myocardial infarction
(n  1), respiratory complications (n  1), multi-organ
failure (n  1), and bowel perforation (n  1). Two
patients died of fatal bleeding caused by an aorto-esophageal
fistula (AEF). Both AEFs were de novo lesions and not
present/symptomatic at the time of stent graft placement.
We consider compression of the esophagus by the pseudo-
aneurysm sac to be the cause, since both patients had large
(8.5 cm, respectively, 10.5 cm) concomitant pseudoaneu-
rysms (Fig 3). Fifteen patients (31%) had postoperative
complications (Table III). Two patients suffered from a
nonprocedure-related postoperative minor stroke, 1 pa-
tient on the second postoperative day after an episode of
atrial fibrillation, and the other in sequel of a fatal multi-
organ failure. No paraplegia was observed. Two patients
with preoperative-impaired renal function showed postop-
eratively a contrast-induced nephropathy requiring tempo-
rary dialysis. Cardiac complications included 5 patients with
myocardial infarction and 1 with an episode of atrial fibril-
lation requiring electric cardioversion. Median intensive
care unit (ICU) stay was 1 day (range, 0-20 days). Clinical
success was achieved in 39/48 patients (81.25%).
Late outcomes. The actuarial survival estimates at 1,
3, and 5 years were 78% 6%, 74% 7%, and 61% 10%,
respectively (Fig 2). Causes of late death were lung carci-
noma in 2 patients, pneumonia in 2, myelodysplastic syn-
drome in 1, and 2 patients died for unknown reason at the
age of 93 and 87, 3½ years and 2½ years postoperatively,
respectively (Fig 4). There was no aortic-related death
during follow-up.
Late endoleaks occurred in 2 patients. This includes 1
patient with an infrarenal proximal type I endoleak at 1 year
postoperatively which could be sealed successfully by em-
bolization. This infrarenal PAU with a contained ruptured
pseudoaneurysm was just below the renal arteries (juxtare-
nal) with a very short, calcified landing zone and was
treated in an emergency procedure with a stent graft that
already covered the renal arteries with bare stents. Due to
high comorbidities, conversion with aortic cross-clamping
was denied and embolization was attempted. A second
patient showed a wire fracture and a consecutive endoleak
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successful endorepair with a bridging maneuver. Reinter-
vention (early and late) was necessary in 4/48 patients
(8.4%).
Subgroup analysis. Subgroup analysis of patients
with acute aortic syndrome vs asymptomatic patients re-
vealed the following results: Mean ASA classification and
logEuroScore were not statistically significant in both
groups (P  .331, P  .111, respectively) representing
equally distributed risk factors in both groups. All periop-
erative deaths (in-hospital mortality) occurred in patients
with acute aortic syndrome (P  .036) but there was no
difference regarding midterm actuarial survival in both
groups (P  .457). All reinterventions were necessary in
symptomatic patients, although this was not statistically
significant (P  .163). Symptomatic patients had a signifi-
cantly larger maximum aortic diameter (median 52.5 mm
vs 40.5 mm; P  .002).
Cox proportional hazard regression showed age (HR,
1.08; 95% CI 1.00-1.18; P  .036) and a maximum aortic
diameter 50 mm (HR, 4.92; 95% CI 1.28-18.92; P 
.021) as independent predictors of death. Female gender
Fig 2. Localization and distribution pattern of all penetrating
aortic ulcer (PAU) (n  56).(HR, 1.053; 95% CI 0.35-3.13; P  .925) and additionalaortic pathologies (HR, 0.319; 95% CI 0.071-1.43; P 
.138) were not predictors of overall survival.
DISCUSSION
The present study indicates that endovascular stent
graft repair in patients with PAU is a minimally invasive
treatment option but associated with a relevant morbidity
and mortality rate. Midterm results showed a sustained
primary treatment success with respect to actuarial survival
and aortic-related death. Moreover, symptomatic patients
showed a significantly worse perioperative outcome but no
difference regardingmidterm cumulative survival. In oppo-
sition to Gottardi et al, age and a maximum aortic diameter
50 mm proved to be independent predictors for death in
our series.22 Additionally, Demers et al found female gen-
der (HR, 7.4; 95% CI 0.8-72.5; P  .08) as an outcome
predictor which could not be approved in this series.13
The prevalence of PAU among patients presenting with
acute aortic syndrome is about 2%-8%.6,7 Although fre-
quently causing the same symptoms, PAU and classic aortic
dissection must be distinguished reliably as they differ
regarding their natural course. Rupture rate in symptom-
atic PAU is reported to be as high as 40% compared to 4%
in Stanford type B dissections.6
Despite defined potential risk factors for disease pro-
gression in symptomatic patients (recurrent/persistent
pain, increase of pleural effusion, PAU morphology, and
location), rupture still remains unpredictable in patients
presenting with PAU.7 Therefore, an aggressive approach
towards surgical treatment, at least in symptomatic pa-
tients, is now generally accepted.12,13,23-26 In opposition
to that, Cho et al presented a retrospective series of 105
patients (75% symptomatic) with conservatively managed
PAU over a 25-year period.27 Medical treatment was asso-
ciated with a significantly lower early mortality rate com-
pared to surgical repair (4% vs 21%) and the authors,
therefore, advocated a rather conservative treatment strat-
egy. However, disease progression with development of
saccular aneurysms occurred in 48% of the medically-
treated patients. Limitations of their study include the large
time period (25 years) with significant changes in imaging
(only 54/105 patients had serial imaging) and surgical
techniques (different devices being used). The median in-
terval (9 days, range, 0-224) between onset of symptoms
and the endovascular procedure in our series seems quite
long, but is comparable to a series by Demers et al with a
mean interval of 17  17 days (range, 6 hours-60 days).13
Reasons for a delayed treatment in our series included
delays in diagnosis, referral to our department, and patient
refusal for treatment in an acute setting. If possible, we
would aim for stent graft placement within 48 hours after
onset of symptoms.
Early mortality after TEVAR in PAU is reported between
0-11% and is thus in line with our results.13,22,25 Regarding
midterm survival, our data confirm 1, 3, and 5-year survival
rates of 85%, 75%, and 60%, respectively.12,13 PAUs fre-
quently represent short, localized lesions, conceptually ideal
targets for stent graft repair. This is supported by a 93.7%
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reintervention rate in our and other series.12,13 Sufficient
landing zones remain the keystoneof a successful exclusion. In
our experience, a minimum of 15 mm seems mandatory. In
the distal arch, this distance needs to bemeasured at the inner
curve using centerline measurements. We recommend left
subclavian artery debranching in order to avoid type II en-
doleakage and minimize paraplegia risk.
Neurological complications (minor stroke) occurred in
2 patients, all nonprocedure-related, although periproce-
dural stroke due to wire manipulation in the aortic arch is
well described for TEVAR.12 No paraplegia was observed
in our series of patients. This is especially remarkable as
11/48 patients (23%) were at an increased risk for paraple-
gia (5 infrarenal AAA repair, 2 infrarenal and thoracic
EVAR, 2 visceral hybrid procedures, 1 open TAAA
surgery, and 1 TEVAR for TAA) but might be explicable
with the short covered aortic length.
The indication for surgical treatment in asymptomatic
Fig 3. Pre- (A) and postoperative computed tomograp
a penetrating aortic ulcer with a large pseudoaneurysm bu
fistula (D).patients remains debatable, whichmakes early andmidtermresults after TEVAR particularly interesting. In our series,
asymptomatic patients had a significantly lower in-hospital
mortality rate than symptomatic patients (0% vs 22.5%). No
differences regarding midterm survival were observed. Our
results compare favorably with a 30-day mortality rate of
12% in asymptomatic patients reported by Cho et al.27 We
are not aware of any other reports comparing surgical
results of asymptomatic and symptomatic patients with
PAU. Cho et al also reported a rupture rate of 4% in
asymptomatic patients during follow-up.27 Furthermore,
no data regarding the natural course in exclusively asymp-
tomatic patients with PAU is available. Thus the actual
proportion of asymptomatic patients showing disease pro-
gression or rupture remains unclear. Series which combine
follow-up in conservatively treated symptomatic and
asymptomatic patients show aortic dilation and aneurysm
formation in about 30-50% which might lead to surgery in
a delayed staged.2,9,10,27 In our series, asymptomatic pa-
tients had a significantly smaller maximum aortic diameter.
giography (CTA) showing a successful exclusion (B) of
t graft infection (C) and evidence of an aorto-esophagealhy an
t stenThis is of special interest as the development of large
JOURNAL OF VASCULAR SURGERY
Volume 48, Number 6 Geisbüsch et al 1367thoracic pseudoaneurysms bares the fatal risk of aorto-
bronchial or -esophageal fistulas as seen in 4/48 patients
(8.3%) in our series. A recently published series by Brown
et al of 115 patients treated with TEVAR for a variety of
thoracic pathologies (4 patients with PAU) showed a graft
infection rate of 5.2% which was lethal in 4 out of 6
patients.28
In our opinion, stent graft repair is also advocated in
asymptomatic patients until future studies define risk fac-
tors for disease progression and rupture in this subgroup of
patients. At present, indication for stent grafting is based on
PAU size, CT-documented progression, and morphologi-
cal aspects of the lesion. Further studies focusing on the
natural course of patients with asymptomatic PAUs are,
therefore, needed.
Limitations. Although this series represents, to our
knowledge, the largest single center study of endovascular-
treated PAU, our study is still limited by the relatively small
number of patients and its retrospective character. It is an
inherent limitation of our approach that we cannot provide
information regarding the natural disease course in this
cohort. It thus remains unclear which patients benefit most
from endovascular treatment. Although the presented mid-
term results seem promising, the durability and effectiveness
of TEVAR has to be proven during long-term follow-up.
CONCLUSION
Endovascular treatment of penetrating aortic ulcers is
associated with a relevant morbidity and mortality rate in
frequently high-comorbid patients. Midterm results could
prove a sustained primary treatment success regarding ac-
tuarial survival and aortic-related death. Endovascular
treatment is warranted in symptomatic patients, although
Fig 4. Kaplan-Meier estimate of actuarial survival in all patients
(n 48) treated with thoracic endovascular aortic repair (TEVAR)
for penetrating aortic ulcers.these patients are at an increased perioperative risk. Generalguidelines for treatment of asymptomatic patients with
PAU have yet to be defined.
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REQUEST FOR SUBMISSION OF SURGICAL ETHICS CHALLENGES ARTICLES
The Editors invite submission of original articles for the Surgical Ethics Challenges section, following the general
format established by Dr. James Jones in 2001. Readers have benefitted greatly from Dr. Jones’ monthly ethics
contributions for more than 6 years. In order to encourage contributions, Dr. Jones will assist in editing them and will
submit his own articles every other month, to provide opportunity for others. Please submit articles under the heading
of “Ethics” using Editorial Manager, and follow the format established in previous issues.
